We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder

By LabMedica International staff writers
Posted on 30 Sep 2019
An improperly functioning molecular network and related biomarkers are expected to help doctors diagnose autism spectrum disorder in young children and to predict the likely severity of symptoms that may develop.

Autism spectrum disorder (ASD) comprises a range of neurodevelopmental mental disorders including autism and Asperger syndrome. More...
Individuals “on the spectrum” often experience difficulties with social communication and interaction, and they often display restricted, repetitive patterns of behavior, interests, or activities. Symptoms are typically recognized between one and two years of age. Long-term problems may include difficulties in performing daily tasks, creating and keeping relationships, and maintaining a job.

ASD is usually diagnosed by subjective observation of clinical symptoms, and no reliable, practical, and objective markers of prognosis currently exist. Hundreds of genes have been implicated in ASD, but the mechanisms through which they contribute to the disorder have not been well defined.

Investigators at the University of California, San Diego (USA) extended the efforts aimed at developing objective tests for detection and prognosis of ASD by analyzing blood gene expression data from 302 one- to four-year-old boys with and without the diagnosis of ASD.

Results revealed the existence of a perturbed gene network that included genes that were highly expressed during fetal brain development. Furthermore, the degree of dysregulation in this network correlated with the severity of ASD symptoms in the toddlers. The network was also found to be dysregulated in ASD cellular models.

"The study shows that through analyses of gene expression from ordinary blood samples, it is possible to study aspects of ASD's fetal molecular origins, uncover the functional impact of hundreds of ASD risk genes that have been discovered over the years, and develop clinical tests of ASD diagnosis and severity prognosis," said senior author Dr. Nathan E. Lewis, associate professor of pediatrics and bioengineering at the University of California, San Diego. "The genetics of ASD are extremely heterogeneous. Hundreds of genes have been implicated, but the underlying mechanisms remain murky. These findings identify how ASD genetics dysregulate a core network that influences brain development at fetal and in the very early years of life and, consequently, the severity of later ASD symptoms."

The ASD study was published in the September 23, 2019, online edition of the journal Nature Neuroscience.

Related Links:
University of California, San Diego


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.